Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

Authors: Karimi, Leena, Alves, Carla L., Terp, Mikkel G., Tuttolomondo, Martina, Portman, Neil, Ehmsen, Sidse, Johansen, Lene E., Bak, Martin, Lim, Elgene, Ditzel, Henrik J.

Source: Cancer communications. 43(6):720-725

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100184965312.0x000001&indx=1&recIds=ETOCvdc_100184965312.0x000001

Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation

Authors: Mousset, Alexandra, Lecorgne, Enora, Bourget, Isabelle, Lopez, Pascal, Jenovai, Kitti, Cherfils-Vicini, Julien, Dominici, Chloé, Rios, Géraldine, Girard-Riboulleau, Cédric, Liu, Bodu, Spector, David L., Ehmsen, Sidse, Renault, Shufang, Hego, Caroline, Mechta-Grigoriou, Fatima, Bidard, François-Clément, Terp, Mikkel Green, Egeblad, Mikala, Gaggioli, Cédric, Albrengues, Jean

Source: In Cancer Cell 10 April 2023 41(4):757-775

Udfordringer ved kræftbehandling til ældre

Authors: Ewertz, Marianne, Ehmsen, Sidse, Jørgensen, Trine Lembrecht

Source: Ugeskrift for læger. 184(6):s. 500-s. 503

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN628855399&indx=1&recIds=ETOCRN628855399

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer.

Authors: Kindt, Charlotte K., Ehmsen, Sidse, Traynor, Sofie, Policastro, Benedetta, Nissen, Nikoline, Jakobsen, Mie K., Hundebøl, Monique F., Johansen, Lene E., Bak, Martin, Arbajian, Elsa, Staaf, Johan, Ditzel, Henrik J., Alves, Carla L.

Source: Frontiers in Oncology; 2025, p1-15, 15p

Subject Terms: METASTATIC breast cancer, HORMONE therapy, CYCLIN-dependent kinase inhibitors, FULVESTRANT, GENE expression, ESTROGEN

Signaling pathways essential for triple‐negative breast cancer stem‐like cells

Authors: Ehmsen, Sidse, Ditzel, Henrik J.

Source: Stem cells. 39(2):133-143

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132317084.0x000001&indx=1&recIds=ETOCvdc_100132317084.0x000001

Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.

Authors: Kindt, Charlotte K., Alves, Carla L., Ehmsen, Sidse, Kragh, Amalie, Reinert, Thomas, Vogsen, Marianne, Kodahl, Annette R., Rønlev, Jeanette D., Ardik, Dilan, Sørensen, Anna L., Evald, Kirstine, Clemmensen, Mia L., Staaf, Johan, Ditzel, Henrik J.

Source: International Journal of Cancer; Dec2024, Vol. 155 Issue 12, p2211-2222, 12p

Subject Terms: CIRCULATING tumor DNA, METASTATIC breast cancer, CYCLIN-dependent kinase inhibitors, HORMONE therapy, GENE amplification, HORMONE receptor positive breast cancer

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study.

Authors: Hansen, Karin Holmskov, Lyng, Maria Bibi, Kodahl, Annette Raskov, Asmussen, Jon Thor, Arshad, Arman, Petersen, Henrik, Krogh, Lotte, Ehmsen, Sidse, Kristensen, Thomas Kielsgaard, Ditzel, Henrik J.

Source: BMC Medical Genomics; 11/21/2024, Vol. 17 Issue 1, p1-9, 9p

Subject Terms: NUCLEOTIDE sequencing, PROGRESSION-free survival, CORE needle biopsy, TREATMENT effectiveness, INVESTIGATIONAL therapies

Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome

Authors: Ehmsen, Sidse, Pedersen, Martin H., Wang, Guisong, Terp, Mikkel G., Arslanagic, Amina, Hood, Brian L., Conrads, Thomas P., Leth-Larsen, Rikke, Ditzel, Henrik J.

Source: In Cell Reports 25 June 2019 27(13):3927-3938

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Authors: Ehmsen, Sidse, Asmussen, Anders, Jeppesen, Stefan S., Nilsson, Anna Christine, Østerlev, Sabina, Vestergaard, Hanne, Justesen, Ulrik S., Johansen, Isik S., Frederiksen, Henrik, Ditzel, Henrik J.

Source: Cancer cell. 39(8):1034-1036

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100136199659.0x000001&indx=1&recIds=ETOCvdc_100136199659.0x000001

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Authors: Ehmsen, Sidse, Pedersen, Rune M., Bang, Line L., Asmussen, Anders, Kragh, Amalie, Holm, Dorte K., Sydenham, Thomas V., Jensen, Thøger G., Jeppesen, Stefan S., Frederiksen, Henrik, Andersen, Thomas E., Ditzel, Henrik J.

Source: Cancer cell. 41(4):649-650

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100188796863.0x000001&indx=1&recIds=ETOCvdc_100188796863.0x000001

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer

Authors: Ehmsen, Sidse, Asmussen, Anders, Jeppesen, Stefan S., Nilsson, Anna Christine, Kragh, Amalie, Frederiksen, Henrik, Ditzel, Henrik J.

Source: Cancer cell. 40(8):800-801

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100178846105.0x000001&indx=1&recIds=ETOCvdc_100178846105.0x000001

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

Authors: Ehmsen, Sidse, Asmussen, Anders, Jeppesen, Stefan S., Nilsson, Anna Christine, Østerlev, Sabina, Kragh, Amalie, Frederiksen, Henrik, Ditzel, Henrik J.

Source: Cancer cell. 40(4):338-339

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100160341534.0x000001&indx=1&recIds=ETOCvdc_100160341534.0x000001

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Authors: Bao, Yi, Oguz, Gokce, Lee, Wee Chyan, Lee, Puay Leng, Ghosh, Kakaly, Li, Jiayao, Wang, Panpan, Lobie, Peter E., Ehmsen, Sidse, Ditzel, Henrik J., Wong, Andrea, Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang

Source: Nature communications. 11(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100187104456.0x000001&indx=1&recIds=ETOCvdc_100187104456.0x000001

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.

Authors: Al-Qasem, Abeer J., Alves, Carla L., Ehmsen, Sidse, Tuttolomondo, Martina, Terp, Mikkel G., Johansen, Lene E., Vever, Henriette, Hoeg, Luna V. A., Elias, Daniel, Bak, Martin, Ditzel, Henrik J.

Source: NPJ Precision Oncology; 9/24/2022, Vol. 6 Issue 1, p1-16, 16p

Subject Terms: CYCLIN-dependent kinase inhibitors, CYCLIN-dependent kinases, AROMATASE inhibitors, BREAST cancer, ESTROGEN, CELL growth

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer.

Authors: Skov, Natascha, Alves, Carla L., Ehmsen, Sidse, Ditzel, Henrik J.

Source: International Journal of Molecular Sciences; Sep2022, Vol. 23 Issue 17, p10053, 13p

Subject Terms: TRIPLE-negative breast cancer, AURORA kinases, B cells, GENE amplification, BREAST cancer, OVERALL survival, CANCER cells

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy.

Authors: Ma, Shijun, Zhao, Yue, Lee, Wee Chyan, Ong, Li-Teng, Lee, Puay Leng, Jiang, Zemin, Oguz, Gokce, Niu, Zhitong, Liu, Min, Goh, Jian Yuan, Wang, Wenyu, Bustos, Matias A., Ehmsen, Sidse, Ramasamy, Adaikalavan, Hoon, Dave S. B., Ditzel, Henrik J., Tan, Ern Yu, Chen, Qingfeng, Yu, Qiang

Source: Nature Communications; 7/15/2022, Vol. 13 Issue 1, p1-18, 18p

Subject Terms: TRIPLE-negative breast cancer, CYTOTOXIC T cells, EPIGENETICS, HYPOXEMIA, KILLER cells, T cells, CHROMATIN

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Authors: Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.

Source: Nature Communications; 9/16/2021, Vol. 12 Issue 1, p1-15, 15p

Subject Terms: BREAST cancer, HORMONE therapy, METASTATIC breast cancer, TREATMENT effectiveness, CANCER cell growth

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.

Authors: Kaminska, Kamila, Akrap, Nina, Staaf, Johan, Alves, Carla L., Ehinger, Anna, Ebbesson, Anna, Hedenfalk, Ingrid, Beumers, Lukas, Veerla, Srinivas, Harbst, Katja, Ehmsen, Sidse, Borgquist, Signe, Borg, Åke, Pérez-Fidalgo, Alejandro, Ditzel, Henrik J., Bosch, Ana, Honeth, Gabriella

Source: Breast Cancer Research; 2/18/2021, Vol. 23 Issue 1, p1-18, 18p

Subject Terms: METASTATIC breast cancer, HORMONE receptor positive breast cancer, PROGNOSIS, ESTROGEN receptors

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.